Navigation Links
MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting

ional multi-agent chemotherapy compared to those who received chemotherapy together with Gliadel Wafer were presented in a poster discussion on Monday June 4, 2007. Eighty-five patients with primary glioblastoma multiforme received surgery with

(n=36) or without (n=49) Gliadel implantation followed by radiotherapy and concurrent temozolomide (TMZ) plus one year of adjuvant rotational multi-agent chemotherapy (lomustine (CCNU), TMZ, and irinotecan), consisting of two cycles of each agent. After a median follow-up of

132 weeks, the group that received Gliadel had an extended median survival of 89.4 weeks (95% CI, 65.1- (Infinity)) compared to 72.7 weeks (95% CI, 57.7-84.3) for patients who did not receive Gliadel.

One- and 2- year survival rates were also increased with the addition of Gliadel (81% vs. 67% and 44% vs. 27%, respectively). A Cox proportional hazards model accounting for the effects of the Recursive Partitioning Analysis (RPA) class was performed, and the effect of Gliadel treatment on survival was found to approach significance (pless than 0.055). Adverse events were similar in patients treated with or without Gliadel and included thrombocytopenia, leukopenia, seizures, fatigue, and gastrointestinal.

Irofulven

Results of a Randomized Phase 2 Trial of Irofulven in Hormone Refractory Prostate Cancer (HRPC) Patients who Failed First-line Docetaxel Treatment

Updated results of a randomized, 3-arm phase 2 study of irofulven

+ prednisone +/- capecitabine compared to mitoxantrone + prednisone in

patients with HRPC were presented in a poster discussion on Saturday, June 2, 2007. A total of 137 patients with documented resistance to first-line treatment with docetaxel were stratified by presence or absence of disease related pain at study entry and assigned to treatment in a 2:2:1 manner (i.e. 4/5 patients received an irofulven-containing regimen). Although the study was not designed for a statistical compa
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... March 23, 2011 Available at ... this patent portfolio discloses methods and techniques related to ...   http://photos.prnewswire.com/prnh/20100614/CG20517LOGO ) Background ... has inherent problems. Orally administered drugs (e.g., tablets or ...
... March 23, 2011 In a letter ... Federal Trade Commission (FTC) warns that a bill shifting ... Mississippi Insurance Commissioner to the Board of Pharmacy "may ... states that the Mississippi legislature should "seriously consider whether ...
Cached Medicine Technology:ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC 2ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC 3Federal Trade Commission: Mississippi SB 2445 'Likely Will Increase Drug Costs, Reduce Competition' 2
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
(Date:7/9/2014)... There has been a sharp increase in the number ... MyChart, the online, interactive service that allows patients to ... providers, schedule appointments, and renew prescriptions. , Over a ... MyChart each year increased five-fold, while the number ... according to a study by Dr. David Gerber ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , , , ... , , , , , ... a binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the ... , , , , ... , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... 2008 -- In the December issue of ... Nickel and associates report on the evidence of ... tract symptoms (LUTS) in men enrolled in the ... of prostate Cancer Events) trial is a 4-year, ...
... Northridge Hospital Medical,Center (Northridge) credits TeleHealth Services, ... the organization,s recent awards and top,accreditation, all ... comfort as its medical experts provide superior ... acute care facility located in Northridge, CA,Northridge ...
... Indication for Bothersome Vaginal Symptom Associated,With Menopause, ... Cream 0.5 g has been approved by the ... indication and a new less,frequent twice-weekly dosing regimen ... intercourse) announced Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ...
... traditional chemotherapy agents with targeted therapies called monoclonal ... in patients with advanced non-small cell lung cancer ... Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ... The combination of bevacizumab and chemotherapy has been ...
... A new research study underway at Cardiff University ... treatment failure among patients with end-stage kidney disease. ... Inflammation Interdisciplinary Research Group at the School of ... the ,Renal Discoveries - The Baxter Extramural Grant, ...
... one of those shoppers who,wake up at 4am on Black ... "It is important not to disturb your circadian rhythm ... SSA. "The body,operates better on a good night,s sleep which ... of dawn the day after Thanksgiving.", SSA retailers nationwide ...
Cached Medicine News:Health News:Relationship between prostate information and lower urinary-tract symptoms evident 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 2Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 4Health News:Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients 2Health News:Cardiff scientists study acute infection in end-stage kidney disease patients 2Health News:Don't Disturb Your Circadian Rhythm This Black Friday 'Sleep In, Nap Later,' says Specialty Sleep Association 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: